A cell response assay for cancer, comprising the steps of: - isolating cancer cells from a biological sample of a cancer patient; - measuring at least one cancer cell type biomarker on the surface of or inside of the cell utilizing a first labeled probe that binds to said cancer cell type biomarker, wherein the at least one cancer cell type biomarker comprises at least one of: (a) a combination of at least one type I cytokeratin and at least one type II cytokeratin; (b) a combination of vimentin and galectin-3; and (c) a combination of N-cadherin and E-cadherin; or (d) an oncoprotein/oncogene selected from the group consisting of HER2/neu, VEGF-165, KRAS, EGFr, WAF, BAX-1, PDGF, Rb, Jagged 1, Notch, VEGF, VEGHR, k-Ras, CAIX, MIB1, MDM, PR, ER, SEL5, SEM1, PI3K, Akt2, twist 1, EML-4, ALK, Braf, DRAFF, c-met, and combinations thereof; - measuring at least one chemo resistance biomarker on the surface of or inside of the cell utilizing a second labeled probe that binds to said chemo resistance biomarker, wherein the at least one chemo resistance biomarker is selected from the group consisting of PL2L piwi like, ADLH, b-integrin, a6 integrin, c-kit, c-met, LIF-R, CXCR4, ESA, CD 20, CD44, CD133, CK5, TRAF2, ABC transporters and combinations thereof; - measuring at least one metastatic potential biomarker on the surface of or inside of the cell utilizing a third labeled probe that binds to said metastatic potential biomarker, wherein the at least one metastatic potential biomarker is selected from the group consisting of - urokinase plasminogen activator (uPA), plasminogen activator inhibitor (PAI-1), CD95, a serine protease, a serine protease inhibitor, a matrix metalloproteinase, a matrix metalloproteinase inhibitor, and combinations thereof; and wherein the at least three labeled probes are measured at different excitations and emission wavelengths. - isolating cancer cells from a biological sample of a cancer patient; - measuring at least one cancer cell type biomarker on the surface of or inside of the cell utilizing a first labeled probe that binds to said cancer cell type biomarker, wherein the at least one cancer cell type biomarker comprises at least one of: (a) a combination of at least one type I cytokeratin and at least one type II cytokeratin; (b) a combination of vimentin and galectin-3; and (c) a combination of N-cadherin and E-cadherin; or (d) an oncoprotein/oncogene selected from the group consisting of HER2/neu, VEGF-165, KRAS, EGFr, WAF, BAX-1, PDGF, Rb, Jagged 1, Notch, VEGF, VEGHR, k-Ras, CAIX, MIB1, MDM, PR, ER, SEL5, SEM1, PI3K, Akt2, twist 1, EML-4, ALK, Braf, DRAFF, c-met, and combinations thereof; (a) a combination of at least one type I cytokeratin and at least one type II cytokeratin; (b) a combination of vimentin and galectin-3; and (c) a combination of N-cadherin and E-cadherin; or (d) an oncoprotein/oncogene selected from the group consisting of HER2/neu, VEGF-165, KRAS, EGFr, WAF, BAX-1, PDGF, Rb, Jagged 1, Notch, VEGF, VEGHR, k-Ras, CAIX, MIB1, MDM, PR, ER, SEL5, SEM1, PI3K, Akt2, twist 1, EML-4, ALK, Braf, DRAFF, c-met, and combinations thereof; - measuring at least one chemo resistance biomarker on the surface of or inside of the cell utilizing a second labeled probe that binds to said chemo resistance biomarker, wherein the at least one chemo resistance biomarker is selected from the group consisting of PL2L piwi like, ADLH, b-integrin, a6 integrin, c-kit, c-met, LIF-R, CXCR4, ESA, CD 20, CD44, CD133, CK5, TRAF2, ABC transporters and combinations thereof; - measuring at least one metastatic potential biomarker on the surface of or inside of the cell utilizing a third labeled probe that binds to said metastatic potential biomarker, wherein the at least one metastatic potential biomarker is selected from the group consisting of - urokinase plasminogen activator (uPA), plasminogen activator inhibitor (PAI-1), CD95, a serine protease, a serine protease inhibitor, a matrix metalloproteinase, a matrix metalloproteinase inhibitor, and combinations thereof; and - urokinase plasminogen activator (uPA), plasminogen activator inhibitor (PAI-1), CD95, a serine protease, a serine protease inhibitor, a matrix metalloproteinase, a matrix metalloproteinase inhibitor, and combinations thereof; and